Ferdowsi University of Mashhad

Document Type : Short Communication


Department of Medicinal Chemistry, Faculty of Pharmacy, Tehran University of Medical Sciences, Tehran, Iran


Coronavirus disease 2019 (COVID-19) has emerged in Wuhan, China, and because of fast transmission, it has led to its extensive prevalence in almost all countries, which has made it a global crisis. Drug repurposing is considered a fast way to discover new applications of the current drugs. This study aims to recognize a possible small molecule as a primary protease inhibitor versus the main protease protein of SARS-CoV-2 by computational programs. Virtual screening procedures like using Molegro Virtual Docker, AutoDock Tool, and AutoDock Vina, were done for more than 1600 FDA-approved medicines downloaded from the ZINC database, were employed to characterize new implied molecule inhibitors for the recently published crystal structure of the main protease protein of SARS-CoV-2. Virtual screening results indicated, many drugs including ARBs, cephalosporins, some kinase inhibitors, HMG CoA reductase, and leukotriene receptor antagonist, may inhibit the main protease of SARS-COV-2. Velpatasvir, Molnupiravir, and Ivermectin were selected by virtual screening methods for further studies to find an efficient ligand for the treatment of COVID-19. Due to some other beneficial features, including anti-infectious, anti-inflammatory properties, and ADME profile, they could be a promising drug nominee for repurposing to the treatment of COVID-19. Velpatasvir was selected by some virtual screening methods for further studies to find a suitable ligand for the treatment of COVID-19. Furthermore, more studies need to approve this data and finally clinical trial needs to be done to examine the efficacy of Velpatasvir for the treatment of covid-19 as an anti-viral agent.


Akl E. A., Jawad M., Lam W. Y., Co C. N., Obeid R. and Irani J. (2013) Motives, beliefs and attitudes towards waterpipe tobacco smoking: a systematic review. Harm Reduction Journal 10:12
Bavishi C., Whelton P. K., Mancia G., Corrao G. and Messerli F. H. (2021) Renin-angiotensin-system inhibitors and all-cause mortality in patients with COVID-19: a systematic review and meta-analysis of observational studies. J Hypertens 39:784-794.
Bharti R. and Shukla S. K. (2021) Molecules against Covid-19: An in silico approach for drug development. Journal of Electronic Science and Technology:100095.
Choudhury S., Moulick D., Borah A., Saikia P. and Mazumder M. K. (2021) In search of drugs to alleviate suppression of the host's innate immune responses against SARS-CoV-2 using a molecular modeling approach. In Silico Pharmacol 9:26.
Cox R. M., Wolf J. D. and Plemper R. K. (2021) Therapeutically administered ribonucleoside analogue MK-4482/EIDD-2801 blocks SARS-CoV-2 transmission in ferrets. Nat Microbiol 6:11-18.
Elfiky A. A. (2020) Ribavirin, Remdesivir, Sofosbuvir, Galidesivir, and Tenofovir against SARS-CoV-2 RNA dependent RNA polymerase (RDRP): A molecular docking study. Life Sci 253:117592.
Jadhav A. K. and Karuppayil S. M. (2021) Topoisomerase II as a target for repurposed antibiotics in Candida albicans: an in silico study. In Silico Pharmacol 9:24.
Kumar R., Kumar V. and Lee K. W. (2021) A computational drug repurposing approach in identifying the cephalosporin antibiotic and anti-hepatitis C drug derivatives for COVID-19 treatment. Comput Biol Med 130:104186.
Li Y., Duche A., Sayer M. R., Roosan D., Khalafalla F. G., Ostrom R. S., Totonchy J. and Roosan M. R. (2021) SARS-CoV-2 early infection signature identified potential key infection mechanisms and drug targets. BMC Genomics 22:125.
Mei M. and Tan X. (2021) Current Strategies of Antiviral Drug Discovery for COVID-19. Front Mol Biosci 8:671263.
Morris G. M., Huey R., Lindstrom W., Sanner M. F., Belew R. K., Goodsell D. S. and Olson A. J. (2009) AutoDock4 and AutoDockTools4: Automated docking with selective receptor flexibility. J Comput Chem 30:2785-2791.
Nosrati M., Shakeran Z. and Shakeran Z. (2018) Frangulosid as a novel hepatitis B virus DNA polymerase inhibitor: a virtual screening study. In Silico Pharmacol 6:10.
Osipiuk J., Azizi S.A., Dvorkin S., Endres M., Jedrzejczak R., Jones K. A., Kang S., Kathayat R. S., Kim Y., Lisnyak V. G., Maki S. L., Nicolaescu V., Taylor C. A., Tesar C., Zhang Y.A., Zhou Z., Randall G., Michalska K., Snyder S. A., Dickinson B. C. and Joachimiak A. (2021) Structure of papain-like protease from SARS-CoV-2 and its complexes with non-covalent inhibitors. Nature Communications 12:743.
Perišić O. (2020) Recognition of Potential COVID-19 Drug Treatments through the Study of Existing Protein-Drug and Protein-Protein Structures: An Analysis of Kinetically Active Residues. Biomolecules 10.
Polamreddy P. and Gattu N. (2019) The drug repurposing landscape from 2012 to 2017: evolution, challenges, and possible solutions. Drug Discov Today 24:789-795.
Pourhajibagher M. and Bahador A. (2020) Computational Biology Analysis of COVID-19 Receptor-Binding Domains: A Target Site for Indocyanine Green Through Antimicrobial Photodynamic Therapy. J Lasers Med Sci 11:433-441.
Sharun K., Tiwari R. and Dhama K. (2020) Protease inhibitor GC376 for COVID-19: Lessons learned from feline infectious peritonitis. Annals of medicine and surgery (2012) 61:122-125.
Soga M., Evans M. J., Cox D. T. C. and Gaston K. J. (2021) Impacts of the COVID-19 pandemic on human–nature interactions: Pathways, evidence and implications. People and Nature 3:518-527.
Sterling T. and Irwin J. J. (2015) ZINC 15 Ligand Discovery for Everyone. Journal of Chemical Information and Modeling 55:2324-2337.